Sichuan Biokin Pharmaceutical Plans RMB3.9 Billion Private Placement for Novel Drug R&D
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...
China-based Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506) announced plans to raise up to RMB3.9...
The Center for Drug Evaluation (CDE) of China has approved LiteDD’s Category 1 product LIT0922...
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced receiving approval from the National Medical...
China-based Jiangsu Cowin Biotech Co., Ltd. (SHA: 688426) announced receiving a Category III medical device...
China-based InventisBio (Shanghai) Co., Ltd (SHA: 688382) announced positive results from the Phase II study...
US giant Bristol-Myers Squibb (BMS, NYSE: BMY) announced receiving marketing approval from the European Commission...
Swiss giant Roche (SWX: ROG, OTCMKTS: RHHBY) announced the launch of the Roche Genentech Innovation...
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced plans to invest RMB130 million...
US giant AbbVie (NYSE: ABBV) announced receiving marketing approval from China’s National Medical Products Administration...
India-based Sun Pharmaceutical Industries Limited (NSE: SUNPHARMA) announced plans to acquire all outstanding shares of...
US giant Pfizer (NYSE: PFE) announced receiving conditional approval from China’s National Medical Products Administration...
Shanghai-based medical device giant MicroPort Scientific Corp. (HKG: 0853) released its 2024 full-year performance estimation....
Shenzhen-based SonoScape Medical Corp. announced receiving marketing approval in China for its S-Fetus prenatal ultrasound...
Zhejiang-based TYK Medicines Inc. (HKG: 2410) announced positive results from a pivotal Phase II study...
On March 10, 2025, Anlong Biopharmaceutical and Sun-Novo Pharmaceutical announced a strategic partnership to advance...
China-based AIM Vaccine Co., Ltd (HKG: 6660) has announced receiving approval from the National Medical...
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
Hangzhou Chance Pharmaceuticals recently announced the completion of a new funding round, led by Zhejiang’s...
China-based Sino Biopharmaceutical Ltd (HKG: 1177) announced acquiring exclusive rights to Nanjing Delova Biotech Co.,Ltd’s...
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that the National...